Kimberly Pechman1, 2, Andrew Lozen1, Kathleen M. Schmainda, 23
1Neurosurgery, Medical College of Wisconsin, Milwaukee, WI, United States; 2Translational Brain Tumor Program, Medical College of Wisconsin, Milwaukee, WI, United States; 3Radiology and Biophysics, Medical College of Wisconsin, Milwaukee, WI, United States
Few systematic studies have examined optimal timing for combining anti-angiogenic therapy with radiation for brain tumor treatment. MRI measures of enhancing tumor volume have proven unreliable since decreases in enhancement may be independent of biologic effect. The purpose of this study was to use rCBV, derived from DSC-MRI, and enhancing volume to optimize combination of anti-VEGF agent, B20, and radiation for treatment of U87 brain tumor models. The studies demonstrate optimal combination occurs when radiation before B20 providing the largest survival benefit.